CO.DON AG

Name ›

Distretto Campania Bioscience

Address/P.O. Box › Postal Code/City › Country › Contact Person › Telephone › Email ›

Website › Number of Employees › Founded (year) ›

Via L. De Crecchio, 7 80138 Naples Italy Amleto D’Agostino, Roberta Lauro +39-081-5667677 direttore@campaniabioscience.it r.lauro@campaniabioscience.it www.campaniabioscience.it 12 2013

Areas of Activity ›

| Industrial Biotechnologies | Innovative Technologies for the Biomedical Industry | Oncology | New Therapies | Genetics and Genomics | Cosmeceuticals, Nutraceuticals, and Functional Foods

External ›

Collaborations | ALISEI –National cluster on life sciences | CEBR –Council of European bioregions | EBN –European Biotechnology Network

Request for ›

Further Collaborations | Boosting collaboration with other EU clusters | EU projects collaboration | Exchanging best practices

(as of 2021)

European Biotechnology

Campania Bioscience operates as a regional institutional cluster, gathering together competences and facilities in the fields of health, biotech and agri-food with the commitment to valorising life sciences regional ecosystem.

Our mission is to generate a positive impact within our national community by sharing innovative products and services and strenghtening regional investment attractiveness and competitiveness, also by contributing to the training of highly qualified professionals in the field of life sciences.

The cluster is composed of 7 research entities, 47 companies and 1 technology transfer agency.

Campania Bioscience key competences: › Pharmacogenomics › Bioinformatics › Industrial Biotechnologies › Oncology › Gene expression and proteomics › Nutraceuticals, cosmeceuticals › Bioremediation and biodegradation › Molecular diagnostics › Gene therapy

We firmly believe that our initiatives play a crucial role in terms of social impact, and for this reason we foster a seamless debate with local and national institutions and stakeholders on how to tackle contemporary challenges with our know-how, innovation, and passion.

Technological trajectories and projects

Campania Bioscience is responsible for the management and implementation of R&D projects, with an overall value of €70 million; a few examples are given below:

Supporting new emerging industries in personalised health

INNOLABS project, together with seven other European clusters, aims to foster collaboration, transfer of knowledge, and opportunities among SMEs belonging

to the fields of ICT, health, bio and medicine from different countries in order to develop, improve, and deliver disruptive technologies mainly related to mHealth, personalised healthcare and ageing populations. INNOLABS will select more than 100 innovative project ideas to accelerate and further support financially and with innovation services.

Creating genetic and genomic meta-cluster

With the GEN.ERA project five EU life sciences clusters and agency partners join and share their international competences and know-how to improve the scale-up of European companies (start-ups and SMEs) involved in the genomics value chain applied to healthcare, by providing a facilitated and successful collective access to a targeted global market.

Developing innovative therapeutic approaches for drug-resistant cancer diseases

The project SATIN focuses on the development of a technology platform for the pre-clinical and clinical trial of innovative therapeutic approaches for the treatment of drug- resistant tumours. The project has an innovative scope by fostering technology transfer activities focused on both immuno-oncology and target tools to selectively attack cancer cells.

Innovative devices for SHAping the Risk of Diabetes

The project IDF-SHARID focuses on the development of diagnostic tools for risk identification and early diagno‘‘sis of diabetes and aims to make molecular prediction of type 2 diabetes and the response or diagnosis of diabetes possible. IDF SHARID will exploit epigenetic and genetic information already available in the literature aiming at create, design, implement and test a prototype genomic LOC capable to identify specific epigenetic and genetic variants associated to individual risk of diabetes.